Biogen (BIIB) PT Raised to $334 at Oppenheimer Amid Aducanuma News
Tweet Send to a Friend
Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $334.00 (from $280.00) while maintaining a Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


